TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

Hypoxia-Specific Drug Tirapazamine Does Not Abrogate Hypoxic Tumor Cells in Combination Therapy with Irinotecan and Methylselenocysteine in Well-Differentiated Human Head and Neck Squamous Cell Carcinoma A253 Xenografts

(2015) Arup Bhattacharya et al.   NEOPLASIA

Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys

(2011) Donald Jung et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

(2011) J. D. Sun et al.   CLINICAL CANCER RESEARCH

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

(2011) G. J. Weiss et al.   CLINICAL CANCER RESEARCH

A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma

(2011) Kristen N. Ganjoo et al.   ONCOLOGY

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

(2010) J. Hu et al.   BLOOD

Development of Hypoxia in a Preclinical Model of Tumor Micrometastases

(2010) Trude G. Simonsen et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group

(2010) Danny Rischin et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

(2009) Michael B. Jameson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone

(2009) O. Tredan et al.   CANCER RESEARCH

1226 Multi-arm Phase IB study of TH-302 in combination with gemcitabine, docetaxel or pemetrexed

(2009) M. Borad et al.   EJC SUPPLEMENTS

Hypoxia in microscopic tumors

(2008) Xiao-Feng Li et al.   CANCER LETTERS

A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies

(2008) K. P. Papadopoulos et al.   CLINICAL CANCER RESEARCH

Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs

(2008) Jian-Xin Duan et al.   JOURNAL OF MEDICINAL CHEMISTRY